Abstract: In embodiments, a method of treating a disease or condition caused by Respiratory Syncytial Virus in a mammal is disclosed including administering to the mammal a composition comprising protocatechuic acid crystals. The mammal may be a human. The composition may include a pharmaceutically acceptable carrier.
Abstract: The present invention relates to a pharmaceutical composition comprising a combination of trazodone or a salt thereof, and gabapentin or a salt or prodrug thereof, said combination having a synergistic effect in the treatment of pain.
Type:
Grant
Filed:
April 15, 2020
Date of Patent:
September 12, 2023
Assignee:
AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.p.A
Abstract: Provided herein are compounds which are useful as antagonists of the muscarinic acetylcholine receptor M1 (mAChR M1); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions.
Abstract: The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.
Type:
Grant
Filed:
December 8, 2022
Date of Patent:
August 29, 2023
Assignee:
Compass Pathfinder Limited
Inventors:
Derek John Londesbrough, Christopher Brown, Julian Scott Northen, Gillian Moore, Hemant Kashinath Patil, David E. Nichols, Megan Croal, Hans Åke Eriksson, George Goldsmith, Molly Tabitha Hickey, Shaun Hurley, Ekaterina Malievskaia, Lindsey Marwood, Drummond E-Wen Joe McCulloch, Laurie Emma Medhurst, Nathan Poulsen, Aslihan Selimbeyoglu, Anaïs Soula, Amanda Tan Shuxiang, Manon Cecile Elisabeth Veraart, Tobias Patrick Whelan, Lars Christian Wilde, Stephen Wright
Abstract: The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like.
Type:
Grant
Filed:
May 28, 2020
Date of Patent:
August 22, 2023
Assignee:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Inventors:
Andrew Wasmuth, Donald W. Landry, Shixian Deng, Banavara L. Mylari, Ravichandran Ramasamy, Ann Marie Schmidt
Abstract: This invention provides synthesis method, crystallization method, etc. for troxacitabine, and also the crystal form and use of troxacitabine.
Abstract: The invention relates to compounds of formula (I) inhibiting Rho Kinase that are meta tyrosine derivatives, processes for preparing such compounds, pharmaceutical compositions containing them and therapeutic use thereof. Particularly the compounds of the invention may be useful in the treatment of many disorders associated with ROCK enzymes mechanisms, such as pulmonary diseases including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension (PAH).
Abstract: The invention provides for treating HBV or HDV infection or inhibiting human sodium taurocholate co-transporting polypeptide (hNTCP) with a polymeric bile acid or salt thereof, and pharmaceutical compositions comprising a polymeric bile acid or salt thereof, and a second HBV or HDV medicament.
Type:
Grant
Filed:
September 28, 2015
Date of Patent:
July 18, 2023
Assignee:
Huahui Health Ltd.
Inventors:
Wenhui Li, Xiangbing Qi, Huan Yan, Yang Liu, Zhiqiang Wang, Bo Peng, Lei Zhang
Abstract: Methods and compositions containing a phorbol ester or a derivative of a phorbol ester are provided for the treatment of chronic and acute conditions. Such conditions may be caused by disease, be symptoms or sequelae of disease. Chronic and acute conditions may be due to viral infections such as HIV and AIDS, neoplastic diseases stroke, kidney disease, urinary incontinence, autoimmune disorders, Parkinson's disease, prostate hypertrophy, aging, or the treatment of such diseases. Additional compositions and methods are provided which employ a phorbol ester or derivative compound in combination with at least one additional agent to yield more effective treatment tools against acute and chronic conditions in mammalian subjects.
Abstract: The present disclosure provides methods of treating inflammation of the upper gastrointestinal tract, especially the esophagus, by administering an oral corticosteroid. In some cases, the methods include treating eosinophilic esophagitis (EoE) by administering an oral corticosteroid in an induction phase and a maintenance phase to improve peak eosinophilic counts and symptoms. In embodiments, the methods include treating EoE by administering the oral corticosteroid at nighttime and/or while the patient is lying down.
Abstract: An antiseptic composition comprising a multivalent cationic antiseptic present in an amount of 0.05 to 0.5 percent based upon the ready to use composition; an anionic compound which is water soluble in an amount of at least 0.1 grams in 100 grams water at 23 deg C., wherein the anionic compound is present at a concentration which would result in precipitation of the multivalent cationic antiseptic in the composition without a solubilizing surfactant present; wherein the composition, with the antiseptic, surfactant and anionic compound combined with each other, is free of precipitate.
Type:
Grant
Filed:
September 11, 2014
Date of Patent:
June 27, 2023
Assignee:
3M INNOVATIVE PROPERTIES COMPANY
Inventors:
Ranjani V. Parthasarathy, Matthew T. Scholz, Joshua X. Xiong, Catherine D. Heapy
Abstract: The present disclosure relates to compounds that bind to at least one of ACAT1/2 and OXCT1/2 and inhibit mitochondrial ATP production, referred to herein as mitoketoscins. Methods of screening compounds for mitochondrial inhibition and anti-cancer properties are disclosed. Also described are methods of using mitoketoscins to prevent or treat cancer, bacterial infections, and pathogenic yeast, as well as methods of using mitoketoscins to provide anti-aging benefits. Specific mitoketoscin compounds are also disclosed.
Abstract: The present disclosure relates to compounds that bind to at least one of ACAT1/2 and OXCT1/2 and inhibit mitochondrial ATP production, referred to herein as mitoketoscins. Methods of screening compounds for mitochondrial inhibition and anti-cancer properties are disclosed. Also described are methods of using mitoketoscins to prevent or treat cancer, bacterial infections, and pathogenic yeast, as well as methods of using mitoketoscins to provide anti-aging benefits. Specific mitoketoscin compounds are also disclosed.
Abstract: Indazole compounds for treating various diseases and pathologies are provided. More particularly, the use of an indazole compound or analogs thereof, in the treatment of inflammatory diseases or disorders is provided.
Type:
Grant
Filed:
December 4, 2020
Date of Patent:
June 6, 2023
Assignee:
BioSplice Therapeutics, Inc.
Inventors:
John Hood, David Mark Wallace, Sunil Kumar KC, Yusuf Yazici, Christopher Swearingen, Luis A Dellamary
Abstract: Methods and compositions for use treating Fragile X syndrome, Angelman syndrome, Fragile X-associated tremor/ataxia syndrome, Autism Spectrum Disorder, Asperger's syndrome, Pervasive developmental disorder not otherwise characterized, Childhood Disintegrative Disorder, Williams syndrome, or Jacobsen syndrome with a compound of Formula 1 as described herein, (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid, or vagabatrin, or pharmaceutically acceptable salts of any of the foregoing, are provided.
Abstract: A method of inhibiting or treating choroidal neovascularization, wherein the method comprises administering an injectable preparation of L-aspartic acid ?-hydroxamate to a patient suffering from choroidal neovascularization, including injecting a first dosage that is 6 mg/kg by weight of the treated subject, and injecting a second dosage that is 3 mg/kg.
Abstract: The invention relates to a carotenoid for use in the treatment or prevention of stress induced conditions, and in particular it relates to the treatment or prevention of a disease mediated by glucocorticoid receptor activity. The invention also relates to a cosmetic method for preventing premature-aging of skin in a subject which comprises administering a carotenoid to said subject. Finally, the invention relates to a method for modulating the activity of a glucocorticoid receptor comprising contacting the receptor with a carotenoid.
Type:
Grant
Filed:
April 11, 2017
Date of Patent:
April 11, 2023
Assignee:
GAT THERAPEUTICS, S.L.
Inventors:
Eugenia Ruiz Canovas, Xavier Álvarez Micó, Olga Durany Turk, Jordi Segura De Yebra, Jaume Mercadé Roca
Abstract: A preconcentrate comprising a fatty acid oil mixture that contains EPA and DHA, preferably in the form of ethyl ester or triglyceride, and at least one surfactant. The preconcentrates are capable of forming a self-nanoemulsifying drug delivery system, a self-microemulsifying drug delivery system or a self-emulsifying drug delivery system (SNEDDS, SMEDDS or SEDDS) in an aqueous solution. The application is also directed to a food supplement preconcentrate.
Type:
Grant
Filed:
March 9, 2010
Date of Patent:
March 28, 2023
Assignee:
PRONOVA BIOPHARMA NORGE AS
Inventors:
Svein Olaf Hustvedt, Preben Houlberg Olesen, Gunnar Berge, Jo Erik Johnsrud Klaveness